Orgenesis Inc. (ORGS)

$1.67

+0.01 (+0.60%)
Rating:
Recommendation:
Neutral
Symbol ORGS
Price $1.67
Beta 0.771
Volume Avg. 0.04M
Market Cap 42.661M
Shares () -
52 Week Range 1.57-5.48
1y Target Est -
DCF Unlevered ORGS DCF ->
DCF Levered ORGS LDCF ->
ROE 53.06% Strong Buy
ROA 38.06% Strong Buy
Operating Margin -
Debt / Equity 67.94% Buy
P/E -
P/B 1.16 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest ORGS news


Ms. Vered Caplan
Healthcare
Biotechnology
NASDAQ Capital Market

Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.